Arbutus Presents Preliminary AB-729 and Pegylated Interferon Alfa-2a Combination Data at the EASL Congress 2023
Portfolio Pulse from Benzinga Newsdesk
Arbutus Biopharma presented preliminary data from its Phase 2a clinical trial evaluating the combination of AB-729 and pegylated interferon alfa-2a in patients with chronic hepatitis B virus at the EASL Congress. The data suggests the treatment was well tolerated and resulted in continued HBsAg declines in some patients.

June 21, 2023 | 7:31 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Arbutus Biopharma's preliminary data from its Phase 2a clinical trial of AB-729 and pegylated interferon alfa-2a for chronic hepatitis B virus shows promising results, potentially boosting the company's stock.
The preliminary data from Arbutus Biopharma's Phase 2a clinical trial suggests that the combination treatment of AB-729 and pegylated interferon alfa-2a is well tolerated and effective in some patients with chronic hepatitis B virus. This positive news could lead to increased investor confidence in the company's pipeline and potential future revenues, resulting in a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100